Last Price
0.595
Today's Change
-0.01 (1.65%)
Day's Change
0.58 - 0.644
Trading Volume
45,283
Exchange: NASDAQ Global Market NASDAQ Global Market
Currency: USD USD
Sector: Healthcare - Healthcare Healthcare - Healthcare
CEO: Dr. Spyridon Papapetropoulos M.D., Ph.D. Dr. Spyridon Papapetropoulos M.D., Ph.D.
Full Time Employees: 8 8
IPO Date: 2021-12-16 2021-12-16
CIK: 0001191070 0001191070
ISIN: US09063M2052 US09063M2052
CUSIP: 09063M205 09063M205
Beta: -0.12 -0.12
Last Dividend: 0.00 0.00
Dcf Diff: -0.10 -0.10
Dcf: 0.69 0.69
Bionomics Limited, a clinical-stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers in Australia and the United States. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which has completed phase 2 clinical trial for the treatment of social anxiety disorder and post-traumatic stress disorder. It also develops BNC375, a small molecule therapeutics for the treatment of cognitive impairment in Alzheimer's disease; BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, a vascular disrupting agent, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer, and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. Bionomics Limited has a licensing agreement with Merck & Co., Inc. The company was incorporated in 1996 and is based in Eastwood, Australia.